We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

24 hedge funds and large institutions have $1.65M invested in vTv Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

20% more funds holding

Funds holding: 20 → 24 (+4)

0% less ownership

Funds ownership: 0.11% → 0.11% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

37% less capital invested

Capital invested by funds: $2.6M → $1.65M (-$955K)

Holders
24
Holders Change
+4
Holders Change %
+20%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PFO
Pathstone Family Office
New Jersey
+$149K
2
TSS
Two Sigma Securities
New York
+$18.6K
3
Millennium Management
Millennium Management
New York
+$6.48K
4
Osaic Holdings
Osaic Holdings
Arizona
+$1.17K
5
Comerica Bank
Comerica Bank
Texas
+$611

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$34.2K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$32.6K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.18K
4
BlackRock
BlackRock
New York
-$880
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$782K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$449K – – –
PFO
3
Pathstone Family Office
New Jersey
$116K +$149K +6,073 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$113K -$32.6K -1,331 -18%
State Street
5
State Street
Massachusetts
$64.4K – – –
BlackRock
6
BlackRock
New York
$25.6K -$880 -36 -3%
Northern Trust
7
Northern Trust
Illinois
$24.1K – – –
Morgan Stanley
8
Morgan Stanley
New York
$16K – – –
TSS
9
Two Sigma Securities
New York
$14.6K +$18.6K +761 New
SQA
10
Simon Quick Advisors
New Jersey
$14.3K – – –
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$9.69K -$34.2K -1,399 -73%
Millennium Management
12
Millennium Management
New York
$5.06K +$6.48K +265 New
FWM
13
Focused Wealth Management
New York
$4.78K – – –
SFCL
14
Strengthening Families & Communities LLC
Massachusetts
$3K – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$1.91K +$1.17K +48 +92%
PA
16
Parallel Advisors
California
$717 – – –
Wells Fargo
17
Wells Fargo
California
$692 +$122 +5 +16%
Comerica Bank
18
Comerica Bank
Texas
$478 +$611 +25 New
CPG
19
Cornerstone Planning Group
New Jersey
$359 – – –
SS
20
Sunbelt Securities
Texas
$287 – – –
Bank of America
21
Bank of America
North Carolina
$180 +$220 +9 New
BNP Paribas Financial Markets
22
BNP Paribas Financial Markets
France
$157 – – –
JP Morgan Chase
23
JP Morgan Chase
New York
$16 +$24 +1 New
Fidelity Investments
24
Fidelity Investments
Massachusetts
$3 -$3.18K -130 Closed
V
25
Veritable
Delaware
– -$180K -6,073 Closed
1
2

VTVT Hedge Fund Activity: Q3 2023 in Review

24 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2023, worth a combined $1.65M — down 37% from $2.6M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VTVT positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Pathstone Family Office, opening a new position worth an estimated $149K. The largest seller was Susquehanna International Group, cutting an estimated $34.2K.

  • 24 institutional investors held vTv Therapeutics (VTVT) as of Q3 2023, up from 20 in Q2 2023.
  • Funds reported $1.65M of vTv Therapeutics stock for Q3 2023, down 37% quarter-over-quarter.
  • 6 funds opened new vTv Therapeutics positions in Q3 2023 and 2 closed out, a net change of +4 holders.
  • The largest vTv Therapeutics buyer in Q3 2023 was Pathstone Family Office, an estimated $149K added.
  • The largest vTv Therapeutics seller in Q3 2023 was Susquehanna International Group, an estimated $34.2K sold.

Based on aggregated 13F filings for Q3 2023.